OxyContin maker Purdue Pharma LP is struggling with slumping sales, a shrinking workforce and restructuring challenges as it battles lawsuits related to the opioid crisis, according to people familiar with the company. Purdue’s revenue is expected to drop below $1 billion this year for the first time in more than a decade, as employees leave and a potential bankruptcy filing looms, people familiar with the matter say. Controlled by members of the billionaire Sackler family, Purdue has also been reviewing the corporate structure...
Purdue Pharma , the manufacturer of controversial opioid OxyContin , is reportedly facing financial difficulties , with revenue expected to fall below $ 1bn in 2019 for the first time in 10 years . Contraction of the workforce , falling sales , and a pending bankruptcy filing , as well as potential restructuring and opioid - related lawsuits across the US , are among the challenges faced by the company . Purdue , which is controlled by the Sackler family , is also thought to be facing a government investigation into fraud at affiliated hospitals . The pharmaceutical 's core product , prescription painkiller OxyContin , is the subject of numerous lawsuits and is experiencing reduced sales .